{"id":36390,"date":"2025-07-01T17:23:05","date_gmt":"2025-07-01T09:23:05","guid":{"rendered":"https:\/\/flcube.com\/?p=36390"},"modified":"2025-07-01T17:23:43","modified_gmt":"2025-07-01T09:23:43","slug":"hutchmeds-orpathys-approved-in-china-for-egfr-met-co-mutation-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36390","title":{"rendered":"HutchMed’s Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC"},"content":{"rendered":"\n

HutchMed (China) Ltd (NASDAQ: HCM<\/a>, HKG: 0013<\/a>) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its MET tyrosine kinase inhibitor (TKI), Orpathys (savolitinib). The drug is approved for use in combination with AstraZeneca\u2019s EGFR inhibitor Tagrisso (osimertinib) to treat patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that has MET amplification following progression on EGFR TKI therapy. <\/p>\n\n\n\n

Approval Significance<\/strong>
This approval marks the third indication for Orpathys in China and establishes it as the only all-oral treatment option currently available for this patient population.<\/p>\n\n\n\n

Clinical Trial Support<\/strong>
The approval is supported by results from the Phase III SACHI study. An interim analysis demonstrated superior efficacy of the Orpathys-Tagrisso combination over chemotherapy, with a median progression-free survival (PFS) of 8.2 months and a favorable safety profile. No new adverse event signals were identified.<\/p>\n\n\n\n

Financial and Development Milestones<\/strong>
The approval has triggered a USD 11 million milestone payment from AstraZeneca to HutchMed. The companies will continue to advance multiple global clinical studies exploring this combination regimen.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that it has received marketing approval from…<\/p>\n","protected":false},"author":1,"featured_media":36391,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[130,16,1105,285,1104,15],"class_list":["post-36390","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-astrazeneca","tag-cancer","tag-hkg-0013","tag-hutchmed","tag-nasdaq-hcm","tag-product-approvals"],"yoast_head":"\nHutchMed's Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its MET tyrosine kinase inhibitor (TKI), Orpathys (savolitinib). The drug is approved for use in combination with AstraZeneca\u2019s EGFR inhibitor Tagrisso (osimertinib) to treat patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that has MET amplification following progression on EGFR TKI therapy.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36390\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"HutchMed's Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC\" \/>\n<meta property=\"og:description\" content=\"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its MET tyrosine kinase inhibitor (TKI), Orpathys (savolitinib). The drug is approved for use in combination with AstraZeneca\u2019s EGFR inhibitor Tagrisso (osimertinib) to treat patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that has MET amplification following progression on EGFR TKI therapy.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36390\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-01T09:23:05+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-01T09:23:43+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0112.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36390#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36390\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"HutchMed’s Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC\",\"datePublished\":\"2025-07-01T09:23:05+00:00\",\"dateModified\":\"2025-07-01T09:23:43+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36390\"},\"wordCount\":188,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36390#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0112.webp\",\"keywords\":[\"AstraZeneca\",\"Cancer\",\"HKG: 0013\",\"HutchMed\",\"NASDAQ: HCM\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36390#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36390\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36390\",\"name\":\"HutchMed's Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36390#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36390#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0112.webp\",\"datePublished\":\"2025-07-01T09:23:05+00:00\",\"dateModified\":\"2025-07-01T09:23:43+00:00\",\"description\":\"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its MET tyrosine kinase inhibitor (TKI), Orpathys (savolitinib). The drug is approved for use in combination with AstraZeneca\u2019s EGFR inhibitor Tagrisso (osimertinib) to treat patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that has MET amplification following progression on EGFR TKI therapy.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36390#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36390\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36390#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0112.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0112.webp\",\"width\":1080,\"height\":608,\"caption\":\"HutchMed's Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36390#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"HutchMed’s Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"HutchMed's Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC - Insight, China's Pharmaceutical Industry","description":"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its MET tyrosine kinase inhibitor (TKI), Orpathys (savolitinib). The drug is approved for use in combination with AstraZeneca\u2019s EGFR inhibitor Tagrisso (osimertinib) to treat patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that has MET amplification following progression on EGFR TKI therapy.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36390","og_locale":"en_US","og_type":"article","og_title":"HutchMed's Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC","og_description":"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its MET tyrosine kinase inhibitor (TKI), Orpathys (savolitinib). The drug is approved for use in combination with AstraZeneca\u2019s EGFR inhibitor Tagrisso (osimertinib) to treat patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that has MET amplification following progression on EGFR TKI therapy.","og_url":"https:\/\/flcube.com\/?p=36390","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-01T09:23:05+00:00","article_modified_time":"2025-07-01T09:23:43+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0112.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36390#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36390"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"HutchMed’s Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC","datePublished":"2025-07-01T09:23:05+00:00","dateModified":"2025-07-01T09:23:43+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36390"},"wordCount":188,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36390#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0112.webp","keywords":["AstraZeneca","Cancer","HKG: 0013","HutchMed","NASDAQ: HCM","Product approvals"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36390#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36390","url":"https:\/\/flcube.com\/?p=36390","name":"HutchMed's Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36390#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36390#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0112.webp","datePublished":"2025-07-01T09:23:05+00:00","dateModified":"2025-07-01T09:23:43+00:00","description":"HutchMed (China) Ltd (NASDAQ: HCM, HKG: 0013) announced that it has received marketing approval from China\u2019s National Medical Products Administration (NMPA) for its MET tyrosine kinase inhibitor (TKI), Orpathys (savolitinib). The drug is approved for use in combination with AstraZeneca\u2019s EGFR inhibitor Tagrisso (osimertinib) to treat patients with locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) that has MET amplification following progression on EGFR TKI therapy.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36390#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36390"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36390#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0112.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0112.webp","width":1080,"height":608,"caption":"HutchMed's Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36390#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"HutchMed’s Orpathys Approved in China for EGFR-MET Co-Mutation NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0112.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36390","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36390"}],"version-history":[{"count":2,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36390\/revisions"}],"predecessor-version":[{"id":36393,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36390\/revisions\/36393"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36391"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36390"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36390"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36390"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}